Skip to search formSkip to main contentSkip to account menu

PIK3CA NP_006209.2:p.H1047R

Known as: Phosphoinositide-3-Kinase Catalytic Alpha Polypeptide H1047R, PIK3CA p.Glu1047Arg, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 110 kDa Catalytic Subunit Alpha H1047R 
A change in the amino acid residue at position 1047 in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform protein… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Background: Blood analytes, as liquid biopsies, are discussed to be surrogate markers for therapy stratification, as serial… 
2017
2017
Detecting and quantifying mutations from circulating tumor DNA (ctDNA) is a new approach for longitudinally monitoring cancer… 
2016
2016
The PIK3CAH1047R mutation is considered to be a potential predictive biomarker for EGFR-targeted therapies. In this study, we… 
2015
2015
Little is known about the role of low-frequency somatic mutations in breast cancer, a cancer that is quite variable in terms of… 
2015
2015
Background: GSK2636771 is a potent, orally bioavailable and selective inhibitor of PI3Kβ (apparent Ki = 0.89 nM), with >900-fold… 
2014
2014
Purpose In complement to anti-EGFR therapy, the targeting of PI3KCA/AKT/mTOR signalling pathway is of particular interest in the… 
Review
2012
Review
2012
The phosphatidylinositol-3-kinase (PI3K) pathway is an important nexus for integration of extracellular and intracellular signals… 
2012
2012
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Hyperactivation of the PI3K pathway through… 
2011
2011
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: Circulating free DNA (cfDNA) represents a…